TrialEuropean journal of heart failure2013

Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF).

John J V McMurray et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.